Home LiteratureArticle Details
PMID: 3922294 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.

Antimicrobial agents and chemotherapy ·Vol. 27 ·No. 3 ·1985-03-00 ·Pages 343-9

Blaser J, Stone BB, Zinner SH

Abstract

Several aminoglycoside dosage regimens were studied in a kinetic in vitro model. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus were exposed in serially placed artificial capillary units to netilmicin concentrations that changed based on human two-compartment pharmacokinetics. The same total dose per 24 h was administered as a continuous infusion (3.7 micrograms/ml) or in 1-h infusions given every 24 (24 micrograms/ml) or 8 h (8 micrograms/ml). The once daily administration showed the best response in terms of either faster killing of E. coli, K. pneumoniae, and S. aureus or greater reduction of the inocula of P. aeruginosa. After 28 h of treatment, however, all regimens reduced the nonpseudomonads by more than 99.99%, whereas all three P. aeruginosa strains regrew to greater than 10(8) CFU/ml due to selection of resistant subpopulations. In contrast to the bactericidal effect of the first dose, no killing occurred after subsequent doses if the ratio of peak drug concentration to MIC was low (less than or equal to 6). These results support the concept of administering high doses of aminoglycosides once every 24 h.

MeSH Terms
Bacteria/drug effects Drug Resistance, Microbial Escherichia coli/drug effects Gentamicins/metabolism Humans Klebsiella pneumoniae/drug effects Microbial Sensitivity Tests Models, Biological Netilmicin/administration & dosage,metabolism,pharmacology Pseudomonas aeruginosa/drug effects Staphylococcus aureus/drug effects Time Factors
Chemicals
Gentamicins Netilmicin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Blaser J
Stone B B
Zinner S H
References (21)
21 references, click to expand
  1. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.
    J Infect Dis. 1983 May;147(5):910-7 PMID: 6842025
  2. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.
    J Infect Dis. 1983 May;147(5):918-32 PMID: 6860416
  3. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin.
    Lancet. 1983 May 21;1(8334):1123-6 PMID: 6133153
  4. Biological variability of multiple dose pharmacokinetics of netilmicin in man.
    Eur J Clin Pharmacol. 1983;24(3):399-406 PMID: 6861854
  5. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.
    N Engl J Med. 1953 Mar 19;248(12):481-8 PMID: 13036982
  6. Infections in cancer patients. Results with gentamicin sulfate therapy.
    Cancer. 1972 Jun;29(6):1697-701 PMID: 4555556
  7. Pseudomonas bacteremia. Review of 108 cases.
    Am J Med. 1976 Apr;60(4):501-8 PMID: 818897
  8. A comparative trial of sisomicin therapy by intermittent versus continuous infusion.
    Am J Med Sci. 1977 Sep-Oct;274(2):179-88 PMID: 602958
  9. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.
    Antimicrob Agents Chemother. 1978 Apr;13(4):570-6 PMID: 352258
  10. Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.
    Arzneimittelforschung. 1980;30(3):491-5 PMID: 7387761
  11. The role of schedule of antibiotic therapy on the neutropenic patient.
    Infection. 1980;Suppl 1:75-81 PMID: 7399718
  12. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics.
    Antimicrob Agents Chemother. 1980 Sep;18(3):377-81 PMID: 6999984
  13. Comparison of minimum inhibitory concentration values determined by three antimicrobic dilution methods for Pseudomonas aeruginosa.
    Am J Clin Pathol. 1981 Jan;75(1):39-44 PMID: 6779623
  14. The in vitro activity of netilmicin against 357 clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.
    Scand J Infect Dis Suppl. 1980;Suppl 23:30-3 PMID: 6782655
  15. An artificial capillary in vitro kinetic model of antibiotic bactericidal activity.
    J Infect Dis. 1981 Dec;144(6):583-7 PMID: 6799585
  16. Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro.
    J Infect Dis. 1982 Apr;145(4):554-60 PMID: 6802906
  17. Effect of the ratio of surface area to volume on the penetration of antibiotics in to extravascular spaces in an in vitro model.
    J Infect Dis. 1982 Sep;146(3):423-8 PMID: 7108283
  18. An in vitro model for the study of antibacterial dosage regimen design.
    J Pharm Sci. 1982 Aug;71(8):861-4 PMID: 7120086
  19. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model.
    J Infect Dis. 1982 Nov;146(5):691-7 PMID: 6813385
  20. Aminoglycoside-selected subpopulations of Pseudomonas aeruginosa: characterization and virulence in normal and leukopenic mice.
    J Lab Clin Med. 1982 Nov;100(5):671-81 PMID: 6813409
  21. Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model.
    J Antibiot (Tokyo). 1982 Jul;35(7):843-9 PMID: 7174537
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1985-03-00
Pages
343-9
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC176274
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com